The Latest Regenerative Medicine Articles from Streetwise Reports


First Cobalt Corp., Oversold, Poised for Rebound This Year?

Contributed Opinion
  ()
Peter Epstein of Epstein Research discusses the market for cobalt and profiles one company whose shares he believes could be at an attractive entry point. read more >

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

Research Report
  ()
By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. read more >

After Financing Close, Biotech's Subsidiary to Operate Independently

Research Report
  ()
An H.C. Wainwright & Co. report explained the purpose of the funding and how any resulting developments would positively impact the former parent company. read more >
Showing Results: 1 to 3 of 3

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"This is a good time to buy TEN; we stay long."
– Clive Maund, CliveMaund.com
"PVG's Brucejack expansion plans are tracking well."
– Andrew Kaip, BMO Capital Markets
"AVU's Sesmarias could be an extension of the ore body at Lousal."
– Siddharth Rajeev, Fundamental Research Corp.
"Adding some possible blue sky to the GSV story is drilling at Lewis."
– Brien Lundin, Gold Newsletter (Jefferson Financial)